by | Apr 25, 2024 | Lupus Foundation of America, News & Events
In systemic lupus erythematosus (SLE), poor disease outcomes often occur in minoritized populations such as Black/African American or Hispanic/Latino populations, and socioeconomically disadvantaged populations. In a new study examining people with systemic lupus...
by | Apr 25, 2024 | Lupus Foundation of America, News & Events
Day-to-day life with lupus can be challenging and take a toll on your mental health. A study examined the prevalence of people with depression and systemic lupus erythematosus (SLE) and found depression was highly prevalent, but often undiagnosed. The study included...
by | Apr 23, 2024 | Lupus Foundation of America, News & Events
A first person has been dosed with the investigational therapy, AlloNK® (also known as AB-101) for treatment of lupus nephritis, (LN, lupus-related kidney disease). This is the first time a person in the US has received an allogeneic NK cell (natural killer cell, a...
by | Apr 20, 2024 | Lupus Foundation of America, News & Events
A new study published in Lupus Science & Medicine found a new diagnostic and disease activity monitoring biomarker for systemic lupus erythematosus (SLE) which could help understand pathogenesis, identify therapeutic targets, and guide clinical management. In the...
by | Apr 19, 2024 | Lupus Foundation of America, News & Events
The U.S. Food & Drug Administration has granted approval for a Phase 1 study to evaluate the safety and efficacy of investigational therapy, CB-010, for treatment of lupus nephritis (LN). The GALLOP study will begin by year-end and will also be evaluated for...
by | Apr 17, 2024 | Lupus Foundation of America, News & Events
Understanding the immune cells that spur inflammation in lupus nephritis (LN) can help advance knowledge of disease progression and identify new treatments. A new study discovered that macrophages, a type of white blood cells that attack and destroy diseased and...